Paper20049950
Direct comparison of two different mesalamine formulations for the induction of remission in patients with ulcerative colitis: a double-blind, randomized study.
Ito H and 7 others. Inflamm Bowel Dis, 2010. Cited by 47 papers, by iCite.
Cite this record
ConductScience Library. Direct comparison of two different mesalamine formulations for the induction of remission in patients with ulcerative colitis: a double-blind, randomized study. Papers, record 20049950. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/20049950
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Direct comparison of two different mesalamine formulations for the induction of remission in patients with ulcerative colitis: a double-blind, randomized study.
- PubMed
- Publication types
- Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- PubMed
Topics21
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Anti-Inflammatory Agents, Non-Steroidal | Major topic |
| Colitis, Ulcerative | Major topic |
| Mesalamine | Major topic |
| Pharmaceutical Preparations | Major topic |
| Adolescent | |
| Adult | |
| Aged | |
| Chemistry, Pharmaceutical | |
| Double-Blind Method | |
| Female | |
| Follow-Up Studies | |
| Humans | |
| Hydrogen-Ion Concentration | |
| Male | |
| Middle Aged | |
| Remission Induction | |
| Severity of Illness Index | |
| Survival Rate | |
| Time Factors | |
| Treatment Outcome | |
| Young Adult |
Source PubMed
References13
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 2684592 | Mesalazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in chronic inflammatory bowel disease. | Drugs | 1989 | https://conductscience.org/library/papers/2684592 | PubMed |
| 2 | 15233681 | Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee. | Am J Gastroenterol | 2004 | https://conductscience.org/library/papers/15233681 | PubMed |
| 3 | 3678967 | Effect of polymer coating on faecal recovery of ingested 5-amino salicylic acid in patients with ulcerative colitis. | Gut | 1987 | https://conductscience.org/library/papers/3678967 | PubMed |
| 4 | 11515850 | Mesalazine 4 g daily given as prolonged-release granules twice daily and four times daily is at least as effective as prolonged-release tablets four times daily in patients with ulcerative colitis. | Inflamm Bowel Dis | 2001 | https://conductscience.org/library/papers/11515850 | PubMed |
| 5 | 1863024 | Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis. A multicenter study. | Ann Intern Med | 1991 | https://conductscience.org/library/papers/1863024 | PubMed |
| 6 | 14075156 | VARIATION BETWEEN OBSERVERS IN DESCRIBING MUCOSAL APPEARANCES IN PROCTOCOLITIS. | Br Med J | 1964 | https://conductscience.org/library/papers/14075156 | PubMed |
| 7 | 26193460 | A critical review of endoscopic indices in ulcerative colitis: inter-observer variation of the endoscopic index. | Clin J Gastroenterol | 2008 | https://conductscience.org/library/papers/26193460 | PubMed |
| 8 | 3569765 | 5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. | Gastroenterology | 1987 | https://conductscience.org/library/papers/3569765 | PubMed |
| 9 | 8338086 | Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa Study Group. | Am J Gastroenterol | 1993 | https://conductscience.org/library/papers/8338086 | PubMed |
| 10 | 3557190 | Metabolism and urinary excretion of 5-amino salicylic acid in healthy volunteers when given intravenously or released for absorption at different sites in the gastrointestinal tract. | Gut | 1987 | https://conductscience.org/library/papers/3557190 | PubMed |
| 11 | 15306569 | Guidelines for the management of inflammatory bowel disease in adults. | Gut | 2004 | https://conductscience.org/library/papers/15306569 | PubMed |
| 12 | 3317057 | Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. | N Engl J Med | 1987 | https://conductscience.org/library/papers/3317057 | PubMed |
| 13 | 3207553 | Delayed-release mesalazine (5-aminosalicylic acid): coat dissolution and excretion in ileostomy subjects. | Br J Clin Pharmacol | 1988 | https://conductscience.org/library/papers/3207553 | PubMed |
Cited by22
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 47 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42204009 | Understanding the Impact of Particle Size and Crystal Habit of Mesalamine Drug Substances on Their Packing, Wetting, and Dissolution Behaviour: A Science-based Approach for Selection of API Vendor. | AAPS PharmSciTech | 2026 | https://conductscience.org/library/papers/42204009 | PubMed |
| 37589498 | Systematic review with meta-analysis: Medical therapies for treatment of ulcerative proctitis. | Aliment Pharmacol Ther | 2023 | https://conductscience.org/library/papers/37589498 | PubMed |
| 37496812 | Efficacy of oral prolonged-release mesalazine in moderately active ulcerative colitis. | JGH Open | 2023 | https://conductscience.org/library/papers/37496812 | PubMed |
| 37007752 | Guidelines for the management of ulcerative colitis. Recommendations of the Polish Society of Gastroenterology and the Polish National Consultant in Gastroenterology. | Prz Gastroenterol | 2023 | https://conductscience.org/library/papers/37007752 | PubMed |
| 36029157 | Definition of mild to moderate ulcerative colitis in clinical trials: A systematic literature review. | United European Gastroenterol J | 2022 | https://conductscience.org/library/papers/36029157 | PubMed |
| 34631051 | pH-dependent vs. constant release of mesalazine in the treatment of ulcerative colitis: Do drug delivery concepts determine therapeutic efficacy? (Review). | Biomed Rep | 2021 | https://conductscience.org/library/papers/34631051 | PubMed |
| 32786164 | Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. | Cochrane Database Syst Rev | 2020 | https://conductscience.org/library/papers/32786164 | PubMed |
| 32398112 | Modified Sijunzi decoction in the treatment of ulcerative colitis in the remission phase: study protocol for a series of N-of-1 double-blind, randomised controlled trials. | Trials | 2020 | https://conductscience.org/library/papers/32398112 | PubMed |
| 31810227 | Switching between Three Types of Mesalazine Formulation and Sulfasalazine in Patients with Active Ulcerative Colitis Who Have Already Received High-Dose Treatment with These Agents. | J Clin Med | 2019 | https://conductscience.org/library/papers/31810227 | PubMed |
| 31269287 | Comparative assessment of budesonide-MMX and mesalamine in active, mild-to-moderate ulcerative colitis: A systematic review and network meta-analysis. | Br J Clin Pharmacol | 2019 | https://conductscience.org/library/papers/31269287 | PubMed |
| 29743838 | Comparison of efficacy of once daily multimatrix mesalazine 2.4 g/day and 4.8 g/day with other 5-aminosalicylic acid preparation in active ulcerative colitis: a randomized, double-blind study. | Intest Res | 2018 | https://conductscience.org/library/papers/29743838 | PubMed |
| 29429045 | Evidence-based clinical practice guidelines for inflammatory bowel disease. | J Gastroenterol | 2018 | https://conductscience.org/library/papers/29429045 | PubMed |
| 28670234 | Comparison of efficacy of multimatrix mesalazine 4.8 g/day once-daily with other high-dose mesalazine in active ulcerative colitis: a randomized, double-blind study. | Intest Res | 2017 | https://conductscience.org/library/papers/28670234 | PubMed |
| 28239313 | Second Korean guidelines for the management of ulcerative colitis. | Intest Res | 2017 | https://conductscience.org/library/papers/28239313 | PubMed |
| 27101467 | Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. | Cochrane Database Syst Rev | 2016 | https://conductscience.org/library/papers/27101467 | PubMed |
| 26884735 | Efficacy and safety of two pH-dependent-release mesalamine doses in moderately active ulcerative colitis: a multicenter, randomized, double-blind, parallel-group study. | Intest Res | 2016 | https://conductscience.org/library/papers/26884735 | PubMed |
| 26558148 | Mesalazine preparations for the treatment of ulcerative colitis: Are all created equal? | World J Gastrointest Pharmacol Ther | 2015 | https://conductscience.org/library/papers/26558148 | PubMed |
| 26347309 | Efficacy of a pH-dependent controlled-release mesalazine based on clinical and endoscopic assessment for ulcerative colitis: a retrospective cohort study. | Clin Exp Gastroenterol | 2015 | https://conductscience.org/library/papers/26347309 | PubMed |
| 25478568 | Therapeutic efficacy of pH-dependent release formulation of mesalazine on active ulcerative colitis resistant to time-dependent release formulation: analysis of fecal calprotectin concentration. | Biomed Res Int | 2014 | https://conductscience.org/library/papers/25478568 | PubMed |
| 25285021 | Long-term efficacy and safety of once-daily mesalazine granules for the treatment of active ulcerative colitis. | Clin Exp Gastroenterol | 2014 | https://conductscience.org/library/papers/25285021 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| FAS | 355 | PubTator's text mining | https://conductscience.org/library/genes/355 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/20049950
GET https://conductscience.org/api/papers/v1/20049950/cited_by?page=2